mirror of
https://github.com/msberends/AMR.git
synced 2026-06-29 11:36:20 +02:00
Built site for AMR@3.0.1.9065: 39b6a25
This commit is contained in:
github-actions
@@ -13,7 +13,7 @@ All antibiogram types adhere to previously described approaches (see Source), an
|
||||
|
||||
<a class="navbar-brand me-2" href="../index.html">AMR (for R)</a>
|
||||
|
||||
<small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">3.0.1.9063</small>
|
||||
<small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">3.0.1.9065</small>
|
||||
|
||||
|
||||
<button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
|
||||
@@ -446,7 +446,7 @@ All antibiogram types adhere to previously described approaches (see Source), an
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># Simulations: 1000 per stratum</span></span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> `Amoxicillin/clavulanic acid` Amoxicillin/clavulanic …¹ Amoxicillin/clavulan…²</span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494; font-style: italic;"><chr></span> <span style="color: #949494; font-style: italic;"><chr></span> <span style="color: #949494; font-style: italic;"><chr></span> </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">1</span> 74.2% (72.1-76.1%) 88.8% (87.2-90.3%) 90.8% (89.3-92.1%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">1</span> 74.2% (72.2-76.1%) 88.8% (87.1-90.3%) 90.8% (89.3-92.2%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># ℹ abbreviated names: ¹`Amoxicillin/clavulanic acid + Ciprofloxacin`,</span></span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># ²`Amoxicillin/clavulanic acid + Gentamicin`</span></span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># Use `ggplot2::autoplot()` or base R `plot()` to create a plot of this antibiogram,</span></span>
|
||||
@@ -465,7 +465,7 @@ All antibiogram types adhere to previously described approaches (see Source), an
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># Simulations: 1000 per stratum</span></span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> `Amoxicillin/clavulanic acid` Amoxicillin/clavulanic …¹ Amoxicillin/clavulan…²</span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494; font-style: italic;"><chr></span> <span style="color: #949494; font-style: italic;"><chr></span> <span style="color: #949494; font-style: italic;"><chr></span> </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">1</span> 74.2% (72.2-76.1%) 88.8% (87.1-90.4%) 90.8% (89.4-92.2%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">1</span> 74.1% (72.1-75.9%) 88.8% (87.1-90.3%) 90.8% (89.5-92.1%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># ℹ abbreviated names: ¹`Amoxicillin/clavulanic acid + Ciprofloxacin`,</span></span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># ²`Amoxicillin/clavulanic acid + Gentamicin`</span></span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># Use `ggplot2::autoplot()` or base R `plot()` to create a plot of this antibiogram,</span></span>
|
||||
@@ -485,8 +485,8 @@ All antibiogram types adhere to previously described approaches (see Source), an
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># Simulations: 1000 per stratum</span></span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> `Syndromic Group` `Piperacillin/tazobactam` Piperacillin/tazobactam + Gentam…¹</span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494; font-style: italic;"><chr></span> <span style="color: #949494; font-style: italic;"><chr></span> <span style="color: #949494; font-style: italic;"><chr></span> </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">1</span> Clinical 74.5% (68.8-79.8%) 93.6% (91.9-95.1%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">2</span> ICU 57.1% (48.2-65.9%) 86.7% (83.3-89.9%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">1</span> Clinical 74.7% (69-80.3%) 93.6% (91.9-95.1%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">2</span> ICU 57% (48.2-66%) 86.7% (83.5-89.7%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">3</span> Outpatient 57.5% (46-68.7%) 76.5% (70.6-82.2%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># ℹ abbreviated name: ¹`Piperacillin/tazobactam + Gentamicin`</span></span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># ℹ 1 more variable: `Piperacillin/tazobactam + Tobramycin` <chr></span></span>
|
||||
@@ -515,14 +515,14 @@ All antibiogram types adhere to previously described approaches (see Source), an
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># Simulations: 1000 per stratum</span></span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> age_group gender `Piperacillin/tazobactam` Piperacillin/tazobactam + Gentami…¹</span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494; font-style: italic;"><chr></span> <span style="color: #949494; font-style: italic;"><chr></span> <span style="color: #949494; font-style: italic;"><chr></span> <span style="color: #949494; font-style: italic;"><chr></span> </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">1</span> 0-24 F 57.7% (29.5-82.6%) 70.5% (45.9-89.1%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">2</span> 0-24 M 59.1% (33-84.2%) 76.1% (55.7-90.6%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">3</span> 25-49 F 67.4% (43.3-90.5%) 93.8% (87.8-97.9%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">4</span> 25-49 M 56.8% (27.5-86.5%) 90.9% (82.4-96.8%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">5</span> 50-74 F 68% (53.3-82.3%) 96.9% (94.7-98.5%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">6</span> 50-74 M 67.1% (56.5-77.5%) 96.8% (94.2-98.8%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">7</span> 75+ F 73.3% (62.9-83.6%) 97.7% (96-98.9%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">8</span> 75+ M 74% (64.2-83.1%) 97.9% (96.1-99.1%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">1</span> 0-24 F 57.7% (29.5-82.1%) 70.5% (46.1-89%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">2</span> 0-24 M 59.3% (33.1-84.2%) 76.2% (55.7-90.9%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">3</span> 25-49 F 67.4% (43.3-90.4%) 93.8% (87.8-97.9%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">4</span> 25-49 M 56.9% (27.1-86.5%) 90.9% (82.6-96.8%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">5</span> 50-74 F 68.1% (53.3-82.6%) 96.9% (94.7-98.5%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">6</span> 50-74 M 67.1% (56.3-77.3%) 96.8% (94.3-98.8%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">7</span> 75+ F 73.3% (62.9-83.7%) 97.7% (96.1-98.9%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">8</span> 75+ M 74% (64.1-82.9%) 97.9% (96-99%) </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># ℹ abbreviated name: ¹`Piperacillin/tazobactam + Gentamicin`</span></span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># ℹ 1 more variable: `Piperacillin/tazobactam + Tobramycin` <chr></span></span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># Use `ggplot2::autoplot()` or base R `plot()` to create a plot of this antibiogram,</span></span>
|
||||
@@ -705,8 +705,8 @@ All antibiogram types adhere to previously described approaches (see Source), an
|
||||
<span class="r-out co"><span class="r-pr">#></span> </span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> |Syndromic Group |Piperacillin/tazobactam |</span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> |:---------------|:-----------------------|</span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> |Clinical |74.6% (68.9-80%) |</span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> |ICU |57% (49.1-65.8%) |</span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> |Clinical |74.7% (68.7-79.8%) |</span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> |ICU |56.8% (48.9-65.7%) |</span>
|
||||
<span class="r-out co"><span class="r-pr">#></span> |Outpatient |57.4% (45.6-68.4%) |</span>
|
||||
<span class="r-in"><span></span></span>
|
||||
<span class="r-in"><span></span></span>
|
||||
@@ -744,7 +744,7 @@ All antibiogram types adhere to previously described approaches (see Source), an
|
||||
|
||||
|
||||
<footer><div class="pkgdown-footer-left">
|
||||
<p><code>AMR</code> (for R). Free and open-source, licenced under the <a target="_blank" href="https://github.com/msberends/AMR/blob/main/LICENSE" class="external-link">GNU General Public License version 2.0 (GPL-2)</a>.<br>Developed at the <a target="_blank" href="https://www.rug.nl" class="external-link">University of Groningen</a> and <a target="_blank" href="https://www.umcg.nl" class="external-link">University Medical Center Groningen</a> in The Netherlands.</p>
|
||||
<p><code>AMR</code> (for R). Free and open-source, licenced under the <a target="_blank" href="https://github.com/msberends/AMR/blob/main/LICENSE" class="external-link">GNU GPL 2.0</a>. Developed at the <a target="_blank" href="https://www.rug.nl" class="external-link">University of Groningen</a> and <a target="_blank" href="https://www.umcg.nl" class="external-link">University Medical Center Groningen</a> in The Netherlands, in collaboration with <a href="https://amr-for-r.org/authors.html">many colleagues from around the world</a>.</p>
|
||||
</div>
|
||||
|
||||
<div class="pkgdown-footer-right">
|
||||
|
||||
Reference in New Issue
Block a user